

Andrew S Bomback

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/214719/publications.pdf>

Version: 2024-02-01

105
papers

4,398
citations

126907

33
h-index

114465

63
g-index

106
all docs

106
docs citations

106
times ranked

5135
citing authors

#	ARTICLE	IF	CITATIONS
1	Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 748-756.	4.5	295
2	Postmortem Kidney Pathology Findings in Patients with COVID-19. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2158-2167.	6.1	241
3	The Modern Spectrum of Renal Biopsy Findings in Patients with Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1718-1724.	4.5	227
4	Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2008, 51, 199-211.	1.9	211
5	Eculizumab in the Treatment of Membranoproliferative Glomerulonephritis. <i>Nephron Clinical Practice</i> , 2015, 128, 270-276.	2.3	165
6	Toward a working definition of C3 glomerulopathy by immunofluorescence. <i>Kidney International</i> , 2014, 85, 450-456.	5.2	164
7	Whole-Exome Sequencing in Adults With Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2018, 168, 100.	3.9	154
8	Updates on the Treatment of Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 2028-2035.	6.1	152
9	Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. <i>Nature Reviews Nephrology</i> , 2012, 8, 634-642.	9.6	131
10	Sugar-sweetened soda consumption, hyperuricemia, and kidney disease. <i>Kidney International</i> , 2010, 77, 609-616.	5.2	124
11	C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. <i>Kidney International</i> , 2018, 93, 977-985.	5.2	123
12	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. <i>Nature Communications</i> , 2020, 11, 1600.	12.8	120
13	Systematic Review and Meta-Analysis of Native Kidney Biopsy Complications. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1595-1602.	4.5	103
14	De Novo and Relapsing Glomerular Diseases After COVID-19 Vaccination: What Do We Know So Far?. <i>American Journal of Kidney Diseases</i> , 2021, 78, 477-480.	1.9	95
15	Rationale and design of the Kidney Precision Medicine Project. <i>Kidney International</i> , 2021, 99, 498-510.	5.2	94
16	Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine. <i>Kidney International</i> , 2021, 100, 461-463.	5.2	87
17	Treatment of nephrotic syndrome with adrenocorticotrophic hormone (ACTH) gel. <i>Drug Design, Development and Therapy</i> , 2011, 5, 147.	4.3	83
18	Treatment of Resistant Glomerular Diseases with Adrenocorticotrophic Hormone Gel: A Prospective Trial. <i>American Journal of Nephrology</i> , 2012, 36, 58-67.	3.1	83

#	ARTICLE	IF	CITATIONS
19	Drug-Induced Glomerular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1291-1299.	4.5	80
20	ANCA-associated glomerulonephritis in the very elderly. <i>Kidney International</i> , 2011, 79, 757-764.	5.2	77
21	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. <i>American Journal of Kidney Diseases</i> , 2019, 73, 218-229.	1.9	68
22	Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 406-413.	4.5	63
23	Future Direction for Using Artificial Intelligence to Predict and Manage Hypertension. <i>Current Hypertension Reports</i> , 2018, 20, 75.	3.5	62
24	Membranous Nephropathy: Approaches to Treatment. <i>American Journal of Nephrology</i> , 2018, 47, 30-42.	3.1	48
25	Kidney Transplantation in C3 Glomerulopathy: A Case Series. <i>American Journal of Kidney Diseases</i> , 2019, 73, 316-323.	1.9	48
26	Rituximab treatment for fibrillary glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1925-1931.	0.7	47
27	Dual Blockade of the Renin-Angiotensin-Aldosterone System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination. <i>American Journal of Hypertension</i> , 2009, 22, 1032-1040.	2.0	46
28	Approach to Diagnosis and Management of Primary Glomerular Diseases Due to Podocytopathies in Adults: Core Curriculum 2020. <i>American Journal of Kidney Diseases</i> , 2020, 75, 955-964.	1.9	46
29	Interaction of Aldosterone and Extracellular Volume in the Pathogenesis of Obesity-Associated Kidney Disease: A Narrative Review. <i>American Journal of Nephrology</i> , 2009, 30, 140-146.	3.1	40
30	The spectrum of kidney biopsy findings in HIV-infected patients in the modern era. <i>Kidney International</i> , 2020, 97, 1006-1016.	5.2	40
31	Complement-Mediated Glomerular Diseases: A Tale of 3 Pathways. <i>Kidney International Reports</i> , 2016, 1, 148-155.	0.8	39
32	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. <i>Kidney International Reports</i> , 2018, 3, 1373-1384.	0.8	39
33	Gestational Diabetes Mellitus Alone in the Absence of Subsequent Diabetes Is Associated With Microalbuminuria. <i>Diabetes Care</i> , 2010, 33, 2586-2591.	8.6	38
34	Sensitivity and Specificity of Pathologic Findings to Diagnose Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1605-1615.	4.5	37
35	Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of collapsing glomerulopathy in renal allografts. <i>Kidney International</i> , 2018, 94, 1189-1198.	5.2	36
36	Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 338-345.	2.3	35

#	ARTICLE	IF	CITATIONS
37	The spectrum of kidney biopsy findings in patients with morbid obesity. <i>Kidney International</i> , 2019, 95, 647-654.	5.2	32
38	Longitudinal Outcomes of COVID-19 Associated Collapsing Glomerulopathy and Other Podocytopathies. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2958-2969.	6.1	31
39	The clinicopathologic spectrum of segmental membranous glomerulopathy. <i>Kidney International</i> , 2021, 99, 247-255.	5.2	30
40	Precision Medicine for Acute Kidney Injury (AKI): Redefining AKI by Agnostic Kidney Tissue Interrogation and Genetics. <i>Seminars in Nephrology</i> , 2018, 38, 40-51.	1.6	28
41	Pilot Study of Return of Genetic Results to Patients in Adult Nephrology. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 651-664.	4.5	28
42	Disordered aldosterone-volume relationship in end-stage kidney disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2009, 10, 230-236.	1.7	27
43	Sugar-sweetened beverage consumption and the progression of chronic kidney disease in the Multi-Ethnic Study of Atherosclerosis (MESA). <i>American Journal of Clinical Nutrition</i> , 2009, 90, 1172-1178.	4.7	27
44	Aldosterone Blockade in CKD: Emphasis on Pharmacology. <i>Advances in Chronic Kidney Disease</i> , 2015, 22, 123-132.	1.4	27
45	Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1833-1839.	4.5	27
46	Mineralocorticoid Receptor Blockade in Chronic Kidney Disease. <i>Blood Purification</i> , 2012, 33, 119-124.	1.8	26
47	Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety. <i>Blood Purification</i> , 2016, 41, 166-170.	1.8	26
48	Lupus Podocytopathy: An Overview. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 369-375.	1.4	25
49	How COVID-19 Has Changed the Management of Glomerular Diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 876-879.	4.5	23
50	Treatment of nephrotic syndrome with adrenocorticotrophic hormone (ACTH). <i>Discovery Medicine</i> , 2011, 12, 91-6.	0.5	22
51	Colonic necrosis due to sodium polystyrene sulfates (Kayexalate). <i>American Journal of Emergency Medicine</i> , 2009, 27, 753.e1-753.e2.	1.6	21
52	A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3442-3446.	0.7	21
53	Definition, identification and treatment of resistant hypertension in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1327-1335.	0.7	21
54	Association of HLA Typing and Alloimmunity With Posttransplantation Membranous Nephropathy: A Multicenter Case Series. <i>American Journal of Kidney Diseases</i> , 2020, 76, 374-383.	1.9	21

#	ARTICLE	IF	CITATIONS
55	Renal Biopsy in the Elderly and Very Elderly: Useful or Not?. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 61-67.	1.4	20
56	Sodium Phosphate Does Not Increase Risk for Acute Kidney Injury After Routine Colonoscopy, Compared With Polyethylene Glycol. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1514-1521.e3.	4.4	20
57	Aldosterone Blockade in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2014, 34, 307-322.	1.6	20
58	Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?. <i>Nature Clinical Practice Nephrology</i> , 2009, 5, 74-75.	2.0	19
59	Racial Differences in Kidney Function Among Individuals With Obesity and Metabolic Syndrome: Results From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2010, 55, S4-S14.	1.9	19
60	Management of Membranous Nephropathy in the PLA2R Era. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 784-786.	4.5	18
61	C3 Glomerulopathy: Pathogenesis and Treatment. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 104-110.	1.4	17
62	The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1066-1072.	4.5	17
63	Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine. <i>Kidney International</i> , 2021, 100, 440-446.	5.2	17
64	Rituximab for Anti-“Glomerular Basement Membrane Disease. <i>Kidney International Reports</i> , 2019, 4, 614-618.	0.8	16
65	Urinary EGF and MCP-1 and risk of CKD after cardiac surgery. <i>JCI Insight</i> , 2021, 6, .	5.0	16
66	Concurrent Anti-“Glomerular Basement Membrane Antibody Disease and Membranous Nephropathy: A Case Series. <i>American Journal of Kidney Diseases</i> , 2021, 78, 219-225.e1.	1.9	16
67	Use of Bortezomib in Heavy-Chain Deposition Disease:“Report“of 3 Cases. <i>American Journal of Kidney Diseases</i> , 2014, 64, 123-127.	1.9	15
68	Anti-Complement Therapy for Glomerular Diseases. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 152-158.	1.4	15
69	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2022, 79, 570-581.	1.9	15
70	Infection-Related Acute Care Events among Patients with Glomerular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1749-1761.	4.5	14
71	Treatment Patterns Among Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN). <i>Kidney International Reports</i> , 2019, 4, 1725-1734.	0.8	13
72	Nonproliferative Forms of Lupus Nephritis. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, 561-569.	1.9	11

#	ARTICLE	IF	CITATIONS
73	Integrated single-cell sequencing and histopathological analyses reveal diverse injury and repair responses in a participant with acute kidney injury: a clinical-molecular-pathologic correlation. <i>Kidney International</i> , 2022, 101, 1116-1125.	5.2	11
74	An Update on Therapies for Proliferative Lupus Nephritis: How Certain Can We Be About the Evidence?. <i>American Journal of Kidney Diseases</i> , 2018, 72, 758-760.	1.9	10
75	Glomerular Diseases in Patients with Diabetes Mellitus: An Underappreciated Epidemic. <i>Kidney360</i> , 2020, 1, 220-222.	2.1	9
76	Anti-glomerular basement membrane nephritis: why we still 'need' the kidney biopsy. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 496-497.	2.9	7
77	Glomerular Diseases in Diabetic Patients: Implications for Diagnosis and Management. <i>Journal of Clinical Medicine</i> , 2021, 10, 1855.	2.4	7
78	Treatment of Monoclonal Gammopathy-associated C3 Glomerulopathy With Daratumumab-based Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e674-e677.	0.4	5
79	ANCA-associated GN to PLEX or not to PLEX?. <i>Nature Reviews Nephrology</i> , 2013, 9, 436-438.	9.6	4
80	Ancestry, genetic risk and health disparities. <i>Nature Reviews Nephrology</i> , 2013, 9, 699-700.	9.6	4
81	Some of the People All of the Time, All of the People None of the Time. <i>American Journal of Kidney Diseases</i> , 2009, 54, A33-A35.	1.9	3
82	Evaluation of the Scored Questionnaire to Identify Individuals with Chronic Kidney Disease in a Community-based Screening Program in Rural North Carolina. , 2014, s2, 007.		3
83	In Search of C3C Tissue Biomarkers. <i>Kidney International Reports</i> , 2019, 4, 1359-1361.	0.8	3
84	Rituximab is preferable to cyclophosphamide for treatment of membranous nephropathy: PRO. <i>Kidney360</i> , 2021, 2, 10.34067/KID.0001842021.	2.1	3
85	Use of ofatumumab and eplerenone in post-transplant recurrence of FSGS. <i>Pediatric Transplantation</i> , 2021, , e14191.	1.0	3
86	An Elderly Man with Fatigue, Dyspnea, and Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 836-838.	4.5	2
87	Aldosterone breakthrough does not alter central hemodynamics. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2017, 18, 147032031773500.	1.7	2
88	Membranous Nephropathy in a Patient With Common Variable Immune Deficiency. <i>Kidney International Reports</i> , 2018, 3, 738-742.	0.8	2
89	Shortening the Duration of Corticosteroid Exposure in Minimal Change Disease: Can We Treat Adults Like Children?. <i>American Journal of Nephrology</i> , 2019, 49, 52-53.	3.1	2
90	Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. <i>Kidney International Reports</i> , 2020, 5, 860-871.	0.8	2

#	ARTICLE	IF	CITATIONS
91	MO126CLINICAL AND BIOMARKER CHARACTERISTICS OF PATIENTS WITH C3G OR IC-MPGN ENROLLED IN TWO PHASE II STUDIES INVESTIGATING THE FACTOR D INHIBITOR DANICOPAN*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	2
92	Belimumab in Lupus Nephritis: New Trial Results Arrive During an Exciting Time for Therapeutics. American Journal of Kidney Diseases, 2021, 77, 984-987.	1.9	2
93	Acute Hyponatremia After a Religious Fast. AACE Clinical Case Reports, 2021, 7, 236-238.	1.1	2
94	Phosphate enemas and GFR decline: it's premature to sound the alarm. Kidney International, 2016, 90, 13-15.	5.2	1
95	American Society of Nephrology Quiz and Questionnaire 2015: Glomerular Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 884-890.	4.5	1
96	A Pregnant Woman with Lupus and Nephrotic-Range Proteinuria. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1534-1537.	4.5	1
97	Membranous nephropathy and cancer in the era of PLA2R testing. Journal of Onco-Nephrology, 2018, 2, 50-55.	0.6	1
98	Validation of Diagnosis Codes to Identify Infection-Related Acute Care Events in Patients With Glomerular Disease. Kidney International Reports, 2021, 6, 3079-3082.	0.8	1
99	Treatment-resistant nephrotic syndrome in dense deposit disease: complement-mediated glomerular capillary wall injury?. Pediatric Nephrology, 2020, 35, 1791-1795.	1.7	1
100	The Evolution of Treating Glomerular Diseases: Letting Science Lead the Way. Advances in Chronic Kidney Disease, 2014, 21, 119-120.	1.4	0
101	A Three-Headed Approach to Kidney Involvement in Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2018, 44, xiii-xiv.	1.9	0
102	Ask and It Shall Be Given. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 594-596.	4.5	0
103	Late Relapses of Membranous Nephropathy: A Case Series. Kidney360, 2021, 2, 974-982.	2.1	0
104	Treatment of Non-Amyloid Monoclonal Gammopathies of Renal Significance (MGRS) with Clone Directed Therapies-Single Center Experience. Blood, 2019, 134, 5565-5565.	1.4	0
105	Proposal for a more practical classification of antineutrophil cytoplasmic antibody-associated vasculitis. CKJ: Clinical Kidney Journal, 2021, 14, 1327-1334.	2.9	0